Riether, Carsten http://orcid.org/0000-0001-7512-513X
Pabst, Thomas
Höpner, Sabine
Bacher, Ulrike
Hinterbrandner, Magdalena
Banz, Yara
Müller, Rouven
Manz, Markus G. http://orcid.org/0000-0002-4676-7931
Gharib, Walid H.
Francisco, David
Bruggmann, Remy
van Rompaey, Luc
Moshir, Mahan
Delahaye, Tim
Gandini, Domenica
Erzeel, Ellen
Hultberg, Anna
Fung, Samson
de Haard, Hans
Leupin, Nicolas
Ochsenbein, Adrian F. http://orcid.org/0000-0003-1773-5436
Article History
Received: 10 April 2019
Accepted: 27 April 2020
First Online: 29 June 2020
Competing interests
: C.R. and A.F.O. are listed as investors on a patent held by the University of Bern on targeting CD70 for the treatment of AML. M.M., T.D., N.L., E.E., D.G., L.V.R., A.H. and H.D.H are employees of argenx. S.F. is a consultant for argenx. All other authors declare no competing interests related to the current study.